UNBELIEVABLE: Christophe weber | History Defined

Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program. The earnings call also mar

MarketBeat · May 15

In an uncertain world, CEOs seek growth while bracing for disruption

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly multipolar world.

Fortune · Feb 20, 2025